Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 16/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | DHFR | P00374 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167592 | 0.93 | DCPS (0.87) | DCPSCYP2D6DHFR | |
| SCHEMBL2166498 | 0.93 | DCPS (1.00) | DCPSCYP2D6DHFR | |
| SCHEMBL2165888 | 0.87 | DCPS (0.77) | DCPSCYP2D6DHFR | |
| SCHEMBL2165847 | 0.87 | DCPS (1.00) | DCPSCYP2D6DHFR | |
| SCHEMBL13929515 | 0.86 | DCPS (0.75) | DCPSCYP2D6DHFR | |
| SCHEMBL2167458 | 0.86 | DCPS (1.00) | DCPSCYP2D6DHFR | |
| SCHEMBL2164740 | 0.86 | DCPS (1.00) | DCPSCYP2D6DHFR | |
| SCHEMBL2167490 | 0.85 | DCPS (0.85) | DCPSCYP2D6DHFR | |
| SCHEMBL4005982 | 0.85 | DCPS (0.74) | DCPSCYP2D6DHFR | |
| SCHEMBL2165987 | 0.85 | DCPS (0.81) | DCPSCYP2D6DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069316-B1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-10-07 | — | — | EP | claimed |
| EP-2615086-A1 | 2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2013-07-17 | — | — | EP | claimed |
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | claimed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | claimed |
| EP-2069316-B1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20140349938-A1 | METHODS OF DIAGNOSING AND TREATING AMYOTROPHIC LATERAL SCLEROSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-11-27 | — | — | US | disclosed |
| EP-2615086-A1 | 2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYT1 | DCPS 1366/4885CYP2D6 3869/4885DHFR 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.